abstract

• The Ebola virus (EBOV) epidemic indicated a great need for prophylactic and therapeutic strategies. The use of plants for the production of biopharmaceuticals is a concept being adopted by the pharmaceutical industry, with an enzyme for human use currently commercialized since 2012 and some plant-based vaccines close to being commercialized. Although plant-based antibodies against EBOV are under clinical evaluation, the development of plant-based vaccines against EBOV essentially remains an unexplored area. The current technologies for the production of plant-based vaccines include stable nuclear expression, transient expression mediated by viral vectors, and chloroplast expression. Specific perspectives on how these technologies can be applied for developing anti-EBOV vaccines are provided, including possibilities for the design of immunogens as well as the potential of the distinct expression modalities to produce the most relevant EBOV antigens in plants considering yields, posttranslational modifications, production time, and downstream processing. © 2017 Rosales-Mendoza, Nieto-Gómez and Angulo.

authors

• Angulo C.
• Nieto-Gómez R.
• Rosales Mendoza Sergio

publication date

• 2017-01-01

published in

• Frontiers in Immunology  Journal

keywords

• Ebola virus; Global vaccination; Glycoprotein antigen; Low-cost vaccine; Molecular pharming; Mucosal immunization; VP antigen antigen; cholera toxin; viral protein; Eastern equine encephalitis virus; Ebolavirus; EBOV GP gene; gene; Human parainfluenza virus 3; immunogenicity; nonhuman; plaque forming cell; protein expression; Review; virus replication

Digital Object Identifier (DOI)

• 10.3389/fimmu.2017.00252

start page

end page

volume

• 8

issue

• MAR